DRUG FORMULATION & BIOAVAILABILITY
|
|
- Jordan Haynes
- 6 years ago
- Views:
Transcription
1 4th DRUG FORMULATION & BIOAVAILABILITY Breakthrough Techniques in Optimizing the Screening, Delivery, Solubility, and Stability of Drugs and Biologics to Enhance Product Life Cycles January 26-28, 2015 Hilton Boston Logan Airport Boston, MA Distinguished Speaker Faculty Includes: Michael Ausborn Site Head, Pharma Research & Early Development F. HOFFMAN LA ROCHE Robert Saklatvala Director, Basic Pharmaceutical Sciences Keith Horspool VP, Pharmaceutical Development BOEHRINGER- INGELHEIM Evan Thackaberry Therapeutic Area Leader, Safety Assessment GENENTECH Riccardo Panicucci Global Head, Chemical & Pharma Profiling NOVARTIS Liping Zhou Senior Scientist, CMC & Engineering IPSEN An excellent event with very focused views of new technologies. Senior CMC Team Leader, ALCON FOUR IN-DEPTH PROGRAM TRACKS FOCUSING ON THE NEWEST BIOAVAILABILITY ENHANCEMENT TECHNIQUES: Modeling & Simulation for Enabled Formulations Managing Formulation Evolution Throughout Drug Life Cycles Team Leadership Styles for Advanced Formulation Development Rethinking Early-Stage Formulation Methods TWO EXTENSIVE INTERACTIVE WORKSHOPS SETTING BEST PRACTICE FOR YOUR GREATEST CHALLENGES: The Industry s Technical and Regulatory Path Forward for Pediatric Formulations Selecting Methodologies, Priorities, and Risks in Salt and Polymorph Screening Sponsors / ALL-NEW CASE STUDIES: Agnostic modalities in future drug development Action plans to proceed without real human data Solid-state chemistry as the next focal point for drug design Latest challenges in simulating supersaturation Adjust to the shorter developmental timelines of fixed-dose combinations Optimal screening approaches for cocrystals Identify and address ph-dependent absorption Risk protocols for photoreactivity and phototoxicity Transition your teams from small to large molecule work Device-based oral biologic delivery
2 WELCOME TO BIO EAST! DEAR COLLEAGUE, The biopharma industry, facing unprecedented regulatory and patent-life pressure, is leaning harder than ever on its formulation teams in order to accelerate time-to-market, expand product life cycles, and maximize revenue. Longstanding challenges to drug solubility are still causing development slowdowns, with 90% of APIs and 40% of drugs at market believed to be poorly-soluble. Only by employing the most innovative new formulation and delivery technologies, and accurately matching each type of molecule to its optimal design and delivery method, can you make significant progress against this challenge. And amidst these ever-present problems, you are now facing new regulatory hurdles, particularly regarding FDA s position on the development of pediatric formulations for all new drug candidates. That is why you cannot afford to miss ExL Pharma s 4th Drug Formulation & Bioavailability conference. Built specifically around feedback from YOU our audience the 2015 conference features an all-new program that targets your greatest and most immediate formulation, solubility, permeability, and bioavailability challenges. Across 3 full days, and featuring more than 6 hours of unparalleled networking, 4 unique program tracks, 2 in-depth interactive workshops, and over 200 of the industry s most distinguished drug formulation, preformulation, and delivery experts, your attendance will prepare you to: 99Develop action plans when real human data is lacking 99Explore the potential for solid-state chemistry as the next breakthrough in drug design 99Select the optimal technologies for advancing drug candidates and maintaining a robust pipeline 99Transition your formulators from small-molecule work to peptides and biologics 99Improve your modeling & simulation tactics for enabled formulations 99Successfully redesign previously-unworkable drugs on a molecular level 99Set priorities and risks in salt and polymorph screening 99Adapt to new scientific and regulatory challenges in the development of pediatric formulations WHO SHOULD ATTEND: Pharmaceutical and biotech executives responsible for: 99Pharmaceutical development 99Preclinical development 99Formulation 99Preformulation 99Medicinal / Analytical / Solid-State Chemistry 99Physicochemistry 99Pharmaceutics 99Pharmacokinetics / DMPK 99Drug Delivery 99Drug Discovery 99Material Science 99Life-Cycle / Portfolio Management 99Toxicology 99Chemical Engineering 99Process R&D THIS PROGRAM WOULD ALSO BE OF INTEREST TO: 99Solubility / Formulation Characterization service providers 99Drug Delivery specialists 99API manufacturers / providers 99CROs 99CMOs I look forward to welcoming you to Boston alongside the leaders of the biopharma industry so we can set next practice together! Sincerely, Matt Greenbaum Matt Greenbaum Senior Conference Producer ExL Pharma mgreenbaum@exlpharma.com Very good examples provided. Great explanations to questions raised! Associate Director, Pharmaceutical Sciences, TAKEDA HOTEL INFORMATION Hilton Boston Logan Airport One Hotel Drive Boston, MA To make reservations, please call and request the negotiated rate for ExL s 4th Drug Formulation & Bioavailability Conference. You may also make reservations using the following weblink: The group rates are available until January 5, SPONSORSHIP & EXHIBITING OPPORTUNITIES Do you want to spread the word about your organization s solutions and services to potential clients who will be attending this event? Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event, or distribute promotional items to attendees. ExL Pharma will work closely with you to customize a package that will suit all of your needs. To learn more about these opportunities, please contact: Jeffrey Friedman Business Development Manager, , jfriedman@exlpharma.com
3 PRE-CONFERENCE WORKSHOP DAY MONDAY, JANUARY 26TH, 2015 WORKSHOP DAY CHAIRPERSON: Keith Horspool, VP, Pharmaceutical Development, BOEHRINGER-INGELHEIM 8:30 Registration and Continental Breakfast for Morning Workshop Participants 9:00 MORNING WORKSHOP: The Industry s Technical and Regulatory Path Forward for Pediatric Formulations Overview of FDA preferences for the developmental timeline of pediatric versions of all new drugs and the need for greater regulatory clarity Brainstorm the development of more discriminating methods than the hundred-person profile Isolate the formulations, ingredients, excipients, and sugars linked to pediatric products that represent the greatest analytical challenge Understand acceptable levels of degradation of pediatric products Extrapolation from adult products to pediatrics when does it work and when doesn t it? Determine the best data submission packages for your PIP and pediatric strategy to different regulatory agencies Reorient your development cycle around these additional formulation needs Manuel Sanchez-Felix, Senior Fellow, Formulation, NOVARTIS Elizabeth Galella, Research Scientist, BRISTOL-MYERS SQUIBB Madhavi Srikoti, Research Scientist, BRISTOL-MYERS SQUIBB Gregory Knipp, Associate Director, Center for Pharmaceutical Processing Research, PURDUE UNIVERSITY 12:00 Luncheon for AM Workshop Participants; Registration for Afternoon Workshop 1:00 AFTERNOON WORKSHOP: Selecting Methodologies, Priorities, and Risks in Salt and Polymorph Screening Target the screening techniques that give you the highest confidence in form stability and solubility Employ different crystallization methods to give the clearest understanding of the compound s purity profile Understand the full scope of relationships between crystallization and screening methods pros and cons of each Maximize form stability during scale-up through exploring different solvents, ratios, and procedures Ensure you maintain the same API ratio in cocrystals during production scale-up compare and contrast different methods Instill new habits of mind for cocrystal screening based on understanding our system, the importance of proper crystallization, and avoiding impractical techniques i.e. Grinding, melting Set best practice on screening and bioavailability testing based on your company s acceptability criteria Measure amorphous content and particle size during and after scale-up of salts to test characterization and solubility Differentiate between essential elements of molecular and formulation screening Determine the ideal material for further stability and solubility steps based on the amount of crystal in your sample Focus patenting strategy on platform technology in cases where you are partnering with other companies on co-developed molecules Predetermine cases where the formulation is so instrumental to function that you must patent both molecule and formulation Marianne Langston, Senior Scientist, Chemical Development, TAKEDA Brian Chekal, Senior Principal Scientist, Crystallization Process Development, PFIZER 4:00 End of Workshop Day Informative and thought-provoking. Great panel discussions! President, AMYLYX PHARMACEUTICALS A very well-organized event! Scientist, DMPK, LEXICON PHARMACEUTICALS
4 MAIN CONFERENCE, DAY ONE TUESDAY, JANUARY 27TH, :45 Registration Opens & Continental Breakfast 8:45 Chairperson s Day One Welcome and Opening Remarks 9:00 KEYNOTE: Future Trends in Drug Formulation: Agnostic Modality Consider a broader focus beyond pill formulations Expand delivery tools in early discovery to design molecules for various administration routes Brainstorm minimally-invasive delivery of poorly permeable drugs Design delivery systems to support better patient adherence Robert Saklatvala, Director, Basic Pharmaceutical Sciences, 9:45 KEYNOTE: An Action Plan for the Lack of Real Human Data Gain insight into formulation methods through awareness of failures as much as successes Grasp the significance of the knowledge gap between preclinical and clinical AUC and CMAX data Reorient knowledge-sharing towards the correlation of specific methodologies with human outcomes Examine the threats to formulation timelines and budgets when different suppliers of the same API yield slightly different purity profiles, processing, performance, and bioequivalence result 10:30 KEYNOTE: Selecting Technologies that Overcome Solubility Challenges and Advance Drug Delivery and Pipeline Robustness Michael Ausborn, Site Head, Pharma Research & Early Development, Basel, F. HOFFMAN-LA ROCHE 11:15 Networking & Refreshment Break 11:45 PANEL: Think Outside the Tablet : Examine and Explain the Slowdown in New Formulation Approaches Understand the limiting scientific explanations behind why no novel widespread formulation approaches have been adopted since solid dispersion technology Identify what the industry is missing through an excessive focus on oral administration Examine the prospects for achievable new drug targeting and device techniques for parenteral delivery that would not require new formulations Riccardo Panicucci, Global Head, Chemical & Pharmaceutical Profiling, NOVARTIS Robert Saklatvala, Director, Basic Pharmaceutical Sciences, Speaker TBD, ABBVIE 12:45 Luncheon Dongmei Qiang, Senior Principal Scientist; Manager, External Collaborations, BOEHRINGER-INGELHEIM TRACK A Modeling & Simulation for Enabled Formulations 1:45 Nanoformulations to Enhance Bioavailability of APIs Suresh Bandari, Principal, ST. PETER S INSTITUTE FOR PHARMACEUTICAL SCIENCES TRACK B Managing Formulation Evolution Throughout Drug Life Cycles Utilization of Formulation Design Space to Accelerate Early Clinical Development of Drug Products How the inclusion of formulation design space within clinical programs gives realtime flexibility in dose and composition of drug products Benefits and applications across the development life cycle including first-inhuman studies and optimization of drug product formulations Case studies: overcoming solubility challenges for BCS II compounds, optimizing MR formulations, performing early assessments of IVIVCs and developing non-oral dosage forms Peter Scholes, CSO, QUOTIENT CLINICAL 2:30 Nanonization of API to Enhance Solubility Exploring opportunities, challenges, and applications of poorly-soluble drugs and NCEs Using top-down methods for particle size reduction to enhance solubility Examining the process parameters and fundamental limits of using bead mills for particle reduction Selecting the correct machine design and materials for specific applications Overview of the clinical benefits and commercialized drugs utilizing nanotechnology David Watkins, Application Manager, Pharmaceuticals, NETZSCH Formulation Bridging and Relative Bioavailability Risk Assessment Throughout Development Regulatory requirements and expectations for bioavailability assessment at multiple development stages g g Biowaivers for changes to drug product Risk-based approach to relative bioavailability decisions Examples of risk assessment outcomes David Sperry, Research Advisor, Small Molecule Design & Development, ELI LILLY
5 MAIN CONFERENCE, DAY ONE TUESDAY, JANUARY 27TH, :15 Latest Challenges in Simulating Supersaturation Overview of the enhancements made to enable supersaturated formulations Select the best methods for predicting how long supersaturated conditions will be sustained Estimate how much supersaturation impacts overall formulation performance Design in-vitro models best capable of predicting and assessing supersaturations Chris Towler, Principal Scientist, NOVARTIS Novel Automated Analysis Methods for Biorelevant Dissolution In vitro methods show how APIs and formulations behave in presence of simulated gastric and intestinal ph and biorelevant media (FaSSIF and FeSSIF); the quest for IVIVC In vivo predictive dissolution methodology; biphasic dissolution to model GI dissolution and absorption Monitoring precipitation from supersaturated solutions and studying the effect of precipitation inhibitors John Comer, CSO, SIRIUS ANALYTICAL 4:00 Networking & Refreshment Break 4:30 Lipid-Based Formulations for Macromolecule Delivery Stephen Tindal, Director, Scientific Affairs, Softgel R&D, CATALENT PHARMA SOLUTIONS CASE STUDY: In-Vitro Experiments and Simulation Approaches to Identify and Address ph-dependent Absorption Use in-vitro dissolution and simulation to design acidified formulations of weak bases that minimize the impact of variable gastric ph Grasp the role of supersaturation in enhancing absorption of poorly-soluble weak bases Utilize buffered formulations and modeling to reduce precipitation of poorlysoluble weak acids Michael Perlman, Senior Scientist II, Pharmaceutical Profiling, MILLENNIUM PHARMACEUTICALS 5:15 Avoid Underpredicting Exposures through Better Modeling of Enabled Formulations Manuel Sanchez-Felix, Senior Fellow, Formulation, NOVARTIS Stepwise Approach to Preformulation and Formulation Development to Maximize Success Paul Sabo, Senior Technician, PDS Formulation Development, PATHEON 6:00 Cocktail Networking Reception 7:00 End of Day One Fascinating mix of industry researchers and technologies. Very well-organized with great content. This event will be a great reference for the future! Scientist, Pharmaceutics, PHARMATEK LABORATORIES Director of Pharmacy Nanotechnology, CONCORDIA UNIVERSITY OF WISCONSIN SCHOOL OF PHARMACY Great presentations - clear and knowledgeable. VP, Product Development R&D, CORERX
6 MAIN CONFERENCE, DAY TWO WEDNESDAY, JANUARY 28TH, :30 Continental Breakfast TRACK A Team Leadership Styles for Advanced Formulation Development 9:00 Overcoming Challenges Formulating High-Drug-Load Fixed- Dose Combinations Gauge impact of API attributes on formulation design strategy and product performance Incorporate solubility-enhancing technology in fixed-dose combinations Formulate APIs to provide differentiated release profiles Use API-sparing tools for identifying and mitigating manufacturing risks Larry Rosen, Director, Formulation & Basic Pharmaceutical Sciences, 9:45 Transition your Formulators from Small-Molecules to Peptides and Biologics Make industry progress towards larger-molecule formulations when companies are not hiring new specialized staff for this purpose Clarify how peptide and biologic specifications are set and formulations are implemented with teams more accustomed to working with small molecules Build off foundational analytical / bioanalytical skills to enable quicker transitions into peptide and biologics work Liping Zhou, Senior Scientist, CMC & Engineering, IPSEN TRACK B Rethinking Early-Stage Formulation Methods Solid-State Chemistry: The Next Focal Point for Drug Design Optimize solid form selection strategy to improve bioavailability and stability Profile key API physical properties to yield physical forms and particles to streamline dosage form design and manufacture Focus on solid-state chemistry and particle properties as the key step in formulation development for a new generation of drugs Weili Yu, Senior Principal Scientist, PFIZER A Strategic Approach to the Regulatory Challenges of Phototoxicity Assessment Track the history of photoreactive compounds and their impact on both solubility and patient phototoxicity Understand the recent ICH regulatory guidelines and interpret the most likely next steps from FDA and EMEA Design protocols and evaluate methods for photoreactivity and phototoxicity risk assessment Evan Thackaberry, Therapeutic Area Leader, Safety Assessment, GENENTECH 10:30 Networking & Refreshment Break PLENARY SESSIONS 11:00 KEYNOTE: Oral Delivery for Biologics: Formulations and Other Potential Strategies Though IV delivery of standard biologics gives 100% bioavailability, oral formulations can sometimes deliver better results or an improved clearance rate Survey the different approaches industry is taking towards oral biologic formulations, through new technical tools and cross-company partnerships Identify why some oral formulations fail and carry those lessons forward into the next generation of biologics Transcend standard formulation challenges through device-based consumable oral delivery methods Riccardo Panicucci, Global Head of Chemical & Pharmaceutical Profiling, NOVARTIS 11:45 In Situ Concentration Monitoring as a Measurement Tool within In Vivo Predictive Dissolution Systems Recognize the greater need for analyzing realtime free drug concentration Identify the challenges to in-situ monitoring presented by bio-relevant simulated fluids and complex foods containing dissolution media Deploy in-situ measurement tools to reduce mechanical complexity of pumping-based sampling systems and provide a very high density of realtime concentration data Gain insight into drug and formulation behavior via combining the dual-chamber dissolution-permeability setup with the ability to monitor concentration in both compartments Konstantin Tsinman, Director, Science & Research, PION 12:30 Luncheon 1:30 Dosing and Dispersability Studies to Model Supersaturation Look into excipient options that would allow you to predict or maintain supersaturation and prevent rapid precipitation Identify the trends in compound crystalline structure most associated with rapid nucleus formation, alignment, and precipitation Properly dose your amorphous solid dispersions for animal studies Gauge the likelihood of maintaining an amorphous state while in oversaturated solution Mengwei Hu, Principal Scientist, Discovery Pharmaceutical Sciences, 2:15 Aligning Multiple Prediction and Evaluation Methods for Preclinical Formulations Choose the best methods for solubility enablement - solubilization or supersaturation? Weigh benefits and limits of preclinical in-silico oral absorption modeling Review early formulation screening techniques Analyze appropriate formulations to support drug candidate selection and risk profiling: PD activity, PK clinical projection, and toxicology studies John Morrison, Senior Research Investigator, Discovery Pharmaceutics, BRISTOL-MYERS SQUIBB 3:00 Molecular Redesign of Previously Unusable Drugs Quantify the amounts of poor drug selectivity and/or excessive toxicity that can be salvaged through new redesign methods Screen through early drug candidates that failed due to excessive toxicity and prioritize them for potential redesign Clearly demonstrate the link between drug potency and targeting potential Redesign drug molecular size and receptor preference to avoid onceunacceptable toxicity levels Suparna Gupta, Principal Scientist, TRANSTECH PHARMA 3:45 Conference Concludes
7 SPONSORS: Ways to Register: Phone: Online: Media Partners: Registration Fees for Attending ExL s 4th Drug Formulation & Bioavailability conference: EARLY-BIRD PRICING Register Before Friday, December 12th, 2014: All-Access Pass: $2,295 Conference and One Workshop: $1,995 Conference Only: $1,695 STANDARD PRICING After December 12th, 2014: All-Access Pass: $2,495 Conference and One Workshop: $2,195 Conference Only: $1,895 ONSITE PRICING All-Access Pass: $2,595 Conference and One Workshop: $2,495 Conference Only: $1,995 GROUP DISCOUNTS Save 25% Per Person when Registering Four For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register 4 at one time) this is a savings of 25% per person. Save 15% Per Person when Registering Three Can only send three? You can still save 15% off of every registration. Questions? Comments? Do you have a question or comments that you would like to be addressed at this event? Would you like to get involved as a speaker or discussion leader? Please Program Director, Matt Greenbaum, at mgreenbaum@exlpharma.com Terms & Conditions By registering for an ExL Events, Inc. ( ExL Pharma ) event, you agree to the following set of terms and conditions listed below: Registration Fee: The fee includes the conference all program materials and designated continental breakfasts lunches and refreshments. Payment: Make checks payable to ExL Events, Inc. and write code C536 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full prior to the commencement of the conference. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options. Group discounts available to individuals must be registered simultaneously and employed by the same organization. Cancellation and Refund Policy If you need to cancel your registration for an upcoming ExL event, please note the following policies derived from the Start Date of the event: Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date. Less than four weeks: A voucher to another ExL event valid for 12 months from the voucher issue date If you cancel at any time after receiving the conference documentation, the voucher issued will be $395 less Substitution Charges: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference. ExL Pharma reserves the right to cancel any conference it deems necessary and will not be responsible for airfare hotel or any other costs incurred by registrants. ExL Pharma s liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date content speakers or venue. * The opinions of ExL speakers do not necessarily reflect those of the companies they represent, nor ExL Events, Inc. Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL Events, Inc. s ( ExL s ) designated speakers and is designed for informational purposes for its attendees, and is NOT INTENDED for purposes of copywriting, nor redistribution to other outlets without the express written permission of ExL s designated speaking parties. Neither ExL, nor its content providers and/ or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. EXL EVENTS, INC. EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY THE CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of or endorse the views or opinions given by any third party content provider. ExL presentations may point to other Internet sites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites
8 Ways to Register: Phone: Online: Yes! Register me for the Conference + 2 Workshops Yes! Register me for the Conference + 1 Workshop Yes! Register me for the Conference Only Method of Payment: Check Credit Card Make checks payable to ExL Events, Inc. Card Type: MasterCard Visa Discover AMEX Card Number: Exp. Date: Name on Card: Signature: Conference Code: C536 Please contact me: I'm interested in marketing opportunities at this event I wish to receive updates on ExL Pharma's upcoming events Name: Title: Company: Dept: Address: City: State: Zip: Phone: Fax: 4th DRUG FORMULATION & BIOAVAILABILITY Breakthrough Techniques in Optimizing the Screening, Delivery, Solubility, and Stability of Drugs and Biologics to Enhance Product Life Cycles January 26-28, 2015 Hilton Boston Logan Airport Boston, MA Michael Ausborn F. HOFFMAN LA ROCHE Sponsors / Robert Saklatvala Keith Horspool BOEHRINGER- INGELHEIM Evan Thackaberry GENENTECH Riccardo Panicucci NOVARTIS Liping Zhou IPSEN
Partnering ACOs. with Summit. 4th. October 27-28, 2014 Hotel Palomar Los Angeles-Westwood, Los Angeles, CA
4th Partnering ACOs October 27-28, 2014 Hotel Palomar Los Angeles-Westwood, Los Angeles, CA with Summit Improve Patient Outcomes and Reduce Costs While Building Valuable Strategic Cross Industry Collaborations
More informationDrug Formulation & Bioavailability WEST
2nd Drug Formulation & Bioavailability WEST Newest Methods for Predicting Challenges to Solubility and Matching your Drug Compounds to the Ideal Formulation and Delivery Techniques June 2-3, 2014 Hilton
More information3rd Annual Global Drug Bioavailability Enhancement Summit
3rd Annual Global Drug Bioavailability Enhancement Summit Event Summary Most drugs on today s market display poor solubility, but the use of modern solubilization technologies can improve a drug product
More informationPharmaceutical/ Biotechnology. May 19-20, 2014 / Princeton Marriott at Forrestal / Princeton, NJ
Life Science Product Complaints Congress Ensure Regulatory Compliance for Effective Processing, Investigating and Trending for PharmaceuTICal, BioTEChnology and MedICal DevICE Complaints May 19-20, 2014
More informationWHAT HAVE WE LEARNED AND WHAT S NEXT?
MARCH 22 23, 2018 WYNDHAM PHILADELPHIA HISTORIC DISTRICT PHILADELPHIA, PA CENTRAL MONITORING SUMMIT WHAT HAVE WE LEARNED AND WHAT S NEXT? Determine the process improvements that must be achieved after
More informationPharmaEd s Solubility Summit 2013
PharmaEd s Solubility Summit 2013 Exploring New Strategies for Optimizing Solubility & Bioavailability of Current and Future Drug Products December 5-6, Racquet Club of Philadelphia, PA Featured Speakers:
More information10th Clinical Performance Metrics & Benchmarking Summit
10th Clinical Performance Metrics & Benchmarking Summit Utilizing Foundational Metrics in a Heavily Data Driven Environment to Ensure High Quality and Efficient Clinical Trials December 4 5, 2013 The Inn
More informationGood Laboratory Practice Compliance
Practice January 26-27, 2017 Hilton Crystal City at Reagan National Airport Arlington, Virginia Use GLP Standards to Remain Compliant and Successful in Preclinical Research Featured Speakers Amanda Ulrey
More informationPharmaEd s Solubility Summit 2013
PharmaEd s Solubility Summit 2013 Exploring New Strategies for Optimizing Solubility & Bioavailability of Current and Future Drug Products December 5-6, Racquet Club of Philadelphia, PA Featured Speakers:
More informationMaximizing Investigator
The ONLY conference for the clinical teams, meeting planners, and solution providers that collaborate to bring engaging investigator meetings to fruition. Maximizing Investigator MEETINGS LEARNING OBJECTIVES
More informationDRUG FORMULATION, SOLUBILITY & BIOAVAILABILITY
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 4th DRUG FORMULATION, SOLUBILITY & BIOAVAILABILITY SUMMIT The Modeling and Enabled Formulation Expertise You Need to Maximize Drug Developability, Avoid Particle Formation,
More informationCMO. Quality Oversight & Risk Management. 4 th. Maintaining Quality and Compliance With CMOs in a Changing Regulatory Environment
4 th CMO Quality Oversight & Risk Management Maintaining Quality and Compliance With CMOs in a Changing Regulatory Environment April 23-24, 2014 Hyatt Regency Boston Boston, MA New for 2014: n REGULATORY
More informationDRUG FORMULATION, SOLUBILITY & BIOAVAILABILITY
7th DRUG FORMULATION, SOLUBILITY & BIOAVAILABILITY SUMMIT March 26-28, 2018 Revere Hotel Boston Common Boston, MA The Latest Formulation Strategies and Predictive Technologies to Accelerate Manufacturing,
More informationAPV Expert Workshop: The Preformulation Tool Box: The Key to Enter Successful Drug Development
Science based design of formulations and manufacturing processes for oral solid dosage forms from preformulation to capable commercial processes APV Expert Workshop: The Preformulation Tool Box: The Key
More informationAdaptive Clinical Trials
MARCH 22 23, 2018 WYNDHAM PHILADELPHIA HISTORIC DISTRICT PHILADELPHIA, PA Adaptive Clinical Trials SYMPOSIUM Analyze Statistics, Data Management, and Operations to Improve Clinical Performance FEATURED
More informationReporting and Compliance Strategies to Drive Aggregate Spend Efficiency SPOTLIGHT FACULTY MEMBERS
6 TH JUNE 8-9, 2015 SONESTA HOTEL PHILADELPHIA, PA AGGREGATE SPEND AND SUNSHINE ACT CONFERENCE Enhance Data Disclosure, Transparency Reporting and Compliance Strategies to Drive Aggregate Spend Efficiency
More information3rd Oral Drug Formulation Innovations June 26-27, 2019 Philadelphia, PA
3rd Oral Drug Formulation Innovations June 26-27, 2019 Philadelphia, PA Uncovering the Future of Formulation Development, Oral Drug Delivery and Innovative Strategies to Accelerate Drug Product Time-To-Market
More informationCLINICAL TRIALS INSPECTION READINESS SUMMIT. Trial Master Files. Inspection Trends. Metrics Analysis. Partner Oversight
5th CLINICAL TRIALS INSPECTION READINESS Ensure Inspection Readiness Through Improved Early Preparation Standards, Organized Documentation and Continuous Vigilance from All Stakeholders August 8-9, 2016
More information8 TH AGGREGATE SPEND CONFERENCE. June 15-16, 2017 Sonesta Philadelphia Rittenhouse Square Philadelphia, PA. Avi Spira CANTEL MEDICAL CORP.
The industry s LEADING educational event for compliance and reporting professionals for almost a decade 8 TH AGGREGATE SPEND AND SUNSHINE ACT CONFERENCE Unlock the Value of Transparent and Efficient Data
More informationRX - TO - OTC SWITCH SUMMIT EVENT HIGHLIGHTS. Hear from an expert speaking faculty, including: THE THIRD ANNUAL FULL LIFE CYCLE SWITCH EVENT
THE THIRD ANNUAL FULL LIFE CYCLE SWITCH EVENT RX - TO - OTC SWITCH SUMMIT Profiling the next wave of over-the-counter availability through an assessment of the safety, marketability and profitability of
More informationRX - TO - OTC. Learning Objectives. Interactive workshop on guiding your organization through and Rx-to-OTC Switch. 4th FEATURED SPEAKERS
4th RX - TO - OTC SWITCH SUMMIT Navigate safety tests, trials, and regulatory compliance while developing complicated business and marketing strategies to ensure a successful switch December 6-7, 2017
More informationSolubility & Bioavailability Summit 2014
Solubility & Bioavailability Summit 2014 Exploring New Strategies for Optimizing Bioavailability of Current and Future Drug Products December 4-5, Racquet Club of Philadelphia, PA Featured Speakers: Neil
More informationDue Diligence Summit
The ONLY life science event focused on the needs of cross-functional due diligence professionals 4th Due Diligence Summit for Life Sciences Benchmark your due diligence practices for evaluating business
More informationAGGREGATE SPEND AND OPEN PAYMENTS CONFERENCE. June 11 12, 2018 Sonesta Philadelphia, Hotel Rittenhouse Square, Philadelphia PA CHAIRPERSON
THE INDUSTRY S PREMIER EVENT FOR STRATEGIES TO OPTIMIZE TRANSPARENCY REPORTING ACROSS GLOBAL 9 TH AGGREGATE SPEND AND OPEN PAYMENTS CONFERENCE June 11 12, 2018 Sonesta Philadelphia, Hotel Rittenhouse Square,
More informationCLINICAL TRIAL BILLING COMPLIANCE BOOT CAMP
CLINICAL TRIAL BILLING COMPLIANCE BOOT CAMP Become Clinical Trial Billing Proficient at the Only Hands-On Workshop to Guide You Through All of Your Billing Compliance Challenges ALL-NEW DATES AND LOCATIONS
More informationImprove early-stage decision-making, optimize lifecycle management and tailor product plans to ensure the successful commercialization of new drugs
2nd December 7-8, 2017 Revere Hotel Boston Common Boston, MA New Product Planning SUMMIT Improve early-stage decision-making, optimize lifecycle management and tailor product plans to ensure the successful
More informationDATA INTEGRITY FOR CLINICAL RESEARCH SUMMIT. Understand the Most Important Trends and the Future Direction of Clinical Data Integrity
MAY 22-23, 2017 HYATT REGENCY MORRISTOWN MORRISTOWN, NJ FOR CLINICAL RESEARCH SUMMIT Understand the Most Important Trends and the Future Direction of Clinical Data Integrity CONFERENCE CHAIR: Leslie Sam
More informationBioequivalence Summit
3rd The leading global event for designing bioequivalence tests for multiple drug delivery systems Bioequivalence Summit Ensure Regulatory Compliance when Demonstrating the Bioequivalence of New Dosage
More informationClinical Performance Metrics and Benchmarking Summit
EXL PHARMA PRESENTS THE ONLY CLINICAL METRICS EVENT FOR THE INDUSTRY 11th Clinical Performance Metrics and Benchmarking Summit Implement Effective Performance Metrics to Monitor Risk, Site Selection, and
More informationTHE ONLY EVENT COVERING A SWITCH FROM END-TO-END. Assessing the Future of Switches in the US and Beyond
THE ONLY EVENT COVERING A SWITCH FROM END-TO-END RX TO OTC SWITCH SUMMIT Assessing the Future of Switches in the US and Beyond DECEMBER 4-5, 2014 HYATT AT THE BELLEVUE PHILADELPHIA, PA FEATURED SPEAKERS:
More informationTHE SECOND ANNUAL FULL LIFE CYCLE SWITCH EVENT. Assessing the Safety, Profitability and Marketability of an OTC Switch
THE SECOND ANNUAL FULL LIFE CYCLE SWITCH EVENT RX - TO - OTC SWITCH SUMMIT Assessing the Safety, Profitability and Marketability of an OTC Switch DECEMBER 3-4, 2015 THE INN AT PENN, A HILTON HOTEL PHILADELPHIA,
More informationHEALTHCARE AD-TECH & PROGRAMMATIC STRATEGY
2ND HEALTHCARE AD-TECH & PROGRAMMATIC STRATEGY Leverage Programmatic and Advanced Ad-Tech Strategies to Effectively Target and Reach Patients and HCPs August 7-8, 2017 Hilton Philadelphia at Penn s Landing
More informationValue-Based Strategies for Reimbursement and Formulary Success
Value-Based Strategies for Reimbursement and Formulary Success Develop a drug value composition that illustrates minimized costs and maximized health outcomes to prove your product deserves formulary access
More informationRX - TO - OTC SWITCH SUMMIT EVENT HIGHLIGHTS THE THIRD ANNUAL FULL LIFE CYCLE SWITCH EVENT FEATURED SPEAKERS: JOIN OUR PRE-CONFERENCE WORKSHOP
THE THIRD ANNUAL FULL LIFE CYCLE SWITCH EVENT RX - TO - OTC SWITCH SUMMIT Profiling the next wave of over-the-counter availability through an assessment of the safety, marketability and profitability of
More informationROOT CAUSE ANALYSIS. 10+ unique perspectives on CAPA systems implementation and management. Sponsors:
5TH SIGNAL DETECTION, ROOT CAUSE ANALYSIS & JANUARY 22-23, 2015 KEY BRIDGE MARRIOTT ARLINGTON, VA Prevent Non-Compliance and Achieve Successful Root Cause Analyses and CAPA Systems Implementation from
More informationLife Science Competition
Life Science Competition Congress November 16-17, 2015 Westin Governor Morris Morristown, NJ Enhance Competitive and Business Intelligence Platforms While Increasing Insight and Learning Strategies to
More informationReal-World Evidence Forum
2017 July 17-18, 2017 // Sheraton Philadelphia University City Hotel // Philadelphia, PA Real-World Evidence Forum Improve health outcomes through the analysis of real-world data to be more efficient in
More informationUtilize Emerging Technologies and Innovative Methods to Improve Audit and Inspection Outcomes, Through Risk Assessment and Quality Assurance
Utilize Emerging Technologies and Innovative Methods to Improve Audit and Inspection Outcomes, Through Risk Assessment and Quality Assurance March 26-27, 2018 Sheraton Philadelphia University Hotel Philadelphia,
More informationStrategic Insights on Drug Development Outsourcing to a Contract Manufacturing Organization in an Evolving Regulatory Landscape
5 TH This is one of the best conferences that I ve attended in my 30+ years of experience Senior Manager, GILEAD QUALITY OVERSIGHT & RISK MANAGEMENT SUMMIT Strategic Insights on Drug Development Outsourcing
More informationDue Diligence Summit
The PREMIER life science event focused on the needs of cross-functional due diligence professionals 5th Due Diligence Summit for Life Sciences Best practices for conducting efficient and effective due
More informationINVESTIGATOR SITE FILES SUMMIT
From the creators of the TMF series INVESTIGATOR SITE FILES SUMMIT Best Practices for Ensuring Compliant, Timely and Quality ISF Management for CROs, Sponsors and Sites SEPTEMBER 19-20, 2016 WYNDHAM BOSTON
More informationJune 5-6, 2014 Hyatt Boston Harbor Hotel Boston, MA. Sami Yusuf, Strategic Opportunities Management,
The The only INDUSTRY EVENT DEDICATED TO ADDRESSING THE NEEDS OF professionals WHO CONDUCT DUE DILIGENCE Due Diligence Summit For Life Sciences Best Practices to Enhance Portfolio Management, In-Licensing
More informationOctober 26-27, 2017 in Mumbai, India
ELECTROLAB, in collaboration with Simulations Plus, presents: The 2-Day GastroPlus Pharmaceutical Development Workshop October 26-27, 2017 in Mumbai, India Electrolab, in collabration with Simulations
More informationUtilize Emerging Technologies and Innovative Methods to Improve Audit and Inspection Outcomes, Through Risk Assessment and Quality Assurance
Utilize Emerging Technologies and Innovative Methods to Improve Audit and Inspection Outcomes, Through Risk Assessment and Quality Assurance March 26-27, 2018 Sheraton Philadelphia University Hotel Philadelphia,
More informationThe State of QbD in the Biopharmaceutical Industry Conference
The State of QbD in the Biopharmaceutical Industry Conference Criticality Assessment, Design Space Implementation and Control 10 11 April 2013 Sheraton Fisherman s Wharf San Francisco, California USA Sponsored
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationDRAFT DOCUMENT FINAL COPY TO REFLECT CONFIRMED. Embed Innovations to Transform Your R&D Procurement Model and. Drive Scientific Activities Efficiency
Embed Innovations to Transform Your R&D Procurement Model and Drive Scientific Activities Efficiency April 30 May 1, 2018 Boston, US This conference exceeded all of my expectations. The topics, speakers
More informationCLINICAL TRIALS. October 15-16, 2014 / Hyatt at the Bellevue / Philadelphia, PA
CLINICAL TRIALS PHASE I & PHASE IIA Decrease Cost and Increase Efficiency in Early Phase Clinical Trials While Addressing Challenges, Biomarker Techniques and Compound Development Strategies October 15-16,
More informationMSL. Summit. Best Practices. 2 ND EUROPEAN Medical & Scientific. Register Now
Bringing Maximum Value to the KOL, Company, and Industry 2 ND EUROPEAN Medical & Scientific ADVISOR and Best Practices MSL Summit 2 0-2 1 O C T O B E R, 2 0 1 1 K E M P I N S K I H O T E L B R I S T O
More information3 RD PARTNERING WITH SUMMIT
PRESENTS 3 RD PARTNERING WITH SUMMIT Identifying New Platforms, Tools, and Strategies to Assist Accountable Care Organizations in Reducing Costs, Improving Quality, and Increasing a Populations Care While
More informationGlobal Pharma Summit
allied academies Global Pharma Summit September 03-04, September 03-04 Theme: Advanced Pharma Technologies-Better Healthcare system Sponsorship For More Details For Queries pharmaceutical@alliedmeetings.com
More informationEXHIBITOR PROSPECTUS
Texas Pediatric Society 2017 Annual Meeting EXHIBITOR PROSPECTUS October 5-6, 2017 Renaissance Dallas at Plano Legacy West Meeting Exhibit i e t i ng a l Me o n a l P 2017 A nnu West y c a g e L Exhibit
More informationClinical Pharmacy 2017
Sponsorship Clinical Pharmacy Theme: Education, Development and Embodying the Principles of Clinical Pharmacy: For Future Success th World Congress on Clinical Pharmacy and Pharmacy Practice December -9,
More informationSponsorship & Branding opportunities
Learn. Connect. Optimize. Tuesday, June 26, 2018 Hyatt regency Hotel, New Brunswick, New Jersey education Forums networking keynote speaker Sponsorship & Branding opportunities Limited Sponsorships available!
More informationAccelerating development of enabled formulations for poorly soluble drugs
Accelerating development of enabled formulations for poorly soluble drugs John McDermott, Executive Director, Drug Product Optimisation Efficacy issues due to inadequate gastrointestinal (GI) absorption
More information2016 Education Leadership Conference (ELC) October 7 9, 2016 Pointe Hilton Tapatio Cliffs Resort, Phoenix, AZ Sponsorship and Exhibit Opportunities
2016 Education Leadership Conference (ELC) October 7 9, 2016 Pointe Hilton Tapatio Cliffs Resort, Phoenix, AZ Sponsorship and Exhibit Opportunities Becoming an ELC sponsor signifies you are committed to
More informationNEW! Processing of cgmp Controlled Raw Materials
NEW! Processing of cgmp Controlled Raw February 27, 2018 New Brunswick, NJ Directed by: Charity Ogunsanya, (Owner/CEO), Pharmabiodevice Consulting LLC Course Topics Include: FDA Regulations 21 CFR 110.80
More informationRole of PBPK based virtual trials modeling in generic product development and regulation
Role of PBPK based virtual trials modeling in generic product development and regulation Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation
More informationAggregate Spend and Sunshine Conference
5 th Aggregate Spend and Sunshine Conference proudly presents Preparing for Disclosure and Dispute Resolution while Applying Lessons Learned June 2-3, 2014 Ritz-Carlton Philadelphia, PA Data Collection
More informationWhen the FDA comes knocking, will your inspection be a success? YES
PRESENTED BY EDUQUEST IN COOPERATION WITH FDA COMPLIANCE BOOT CAMP 2017 I Auditing, Data Integrity, and Quality Systems GET FIVE DAYS OF HANDS-ON, INTERACTIVE TRAINING! YOUR INSTRUCTORS OCT. 16-20, 2017
More information2015 PHARMACEUTICAL MARKET ACCESS IN CHINA SUMMIT
2015 PHARMACEUTICAL MARKET ACCESS IN CHINA SUMMIT September 24 th, 2015 Beijing, China Hear Critical Regulatory Update from Previous & Priority Inviting Keynote Speakers China Food & Drug Administration
More information2018 ADAM Annual Meeting
2018 ADAM Annual Meeting Exhibitor & Partner Prospectus February 12-14, 2018 Exhibit Show February 13 San Diego, CA Exhibit Application Deadline: November 22, 2017 APPLY EARLY TO ENSURE A SPOT! ADAM is
More informationPDA Bioburden and Biofilm Workshop
The Parenteral Drug Association presents the... PDA Bioburden and Biofilm Workshop Controlling Microbial Contamination to Assure Product Quality, Patient Safety Save $100 when you register for the workshop
More informationOverview Stability testing is an essential part of drug development which ensures the quality, safety and efficacy of the drug for the lifetime of the drug product. Appropriate storage conditions can only
More informationFOOD RECALLS & TRACEABILITY SUMMIT
REGISTER BY AUGUST 22, 2014 AND SAVE $200! FOOD RECALLS & TRACEABILITY SUMMIT October 27-28, 2014 Hilton Old Town Alexandria, VA Build a Pre-Emptive Recall Strategy Adapt to FSMA Regulations Optimize Product
More informationModel-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 Biopharmaceutical Classification System Approximately 80% of drugs in the pharmaceutical compounds
More informationFrom Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase
An Executive Summary From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase Leveraging knowledge about an API s physicochemical properties
More informationWhen the FDA comes knocking, will your inspection be a success? YES
PRESENTED BY EDUQUEST IN COOPERATION WITH FDA COMPLIANCE BOOT CAMP 2018 I Auditing, Data Integrity, and Quality Systems GET FIVE DAYS OF HANDS-ON, INTERACTIVE TRAINING! YOUR INSTRUCTORS MAY 14-18, 2018
More informationEXHIBIT & SPONSORSHIP OPPORTUNITIES A (GREEN AND) GOLDEN OPPORTUNITY
EXHIBIT & SPONSORSHIP OPPORTUNITIES & CONFERENCE STATE BA R OF WIS CON SIN June 13-14 ter Hyatt Regency/KI Convention Cen Green Bay, Wisconsin Annual Meeting 2019 A (GREEN AND) GOLDEN OPPORTUNITY Get into
More informationTRIAL MASTER FILE TMF EUROPEAN SUMMIT OCTOBER, 2014 HILTON LONDON KENSINGTON
3RD ANNUAL THE ONLY CONFERENCE IN EUROPE COMPLETELY DEDICATED TO TRIAL MASTER FILES! EUROPEAN TRIAL MASTER FILE SUMMIT Maintaining a Compliant Electronic and Paper TMF for Audits and Inspections 20 21
More informationBiowaivers: BCS and IVIVC
Workshop in Celebration of 25 th Anniversary of the School of Pharmacy School of Pharmacy Faculty of Medicine The Chinese University of Hong Kong Biopharmaceutics of Modified Release Products and Challenging
More information2019 BANK PRESIDENTS SEMINAR. Sponsorship Information. January 7 9, Four Seasons Biltmore Santa Barbara, CA
2019 BANK PRESIDENTS SEMINAR January 7 9, 2019 Four Seasons Biltmore Santa Barbara, CA Sponsorship Information For more information about sponsorships, contact Rosemary Mignano at (916) 438-4435 or rmignano@westernbankers.com
More informationEXHIBITOR & SPONSORSHIP PROSPECTUS
EXHIBITOR & SPONSORSHIP PROSPECTUS OCTOBER 25-26, 2018 KALAHARI RESORT WISCONSIN DELLS Bringing You Face-to-face with Wisconsin Attorneys Plan now to be a part of Wisconsin s largest Legal Expo Meet hundreds
More informationA (GREEN AND) GOLDEN OPPORTUNITY State Bar of Wisconsin Annual Meeting & Conference June 16-17, 2016 Green Bay, Wisconsin
A (GREEN AND) GOLDEN OPPORTUNITY State Bar of Wisconsin Annual Meeting & Conference June 16-17, 2016 Green Bay, Wisconsin Exhibit and Sponsorship Opportunities Get into the game at the 2016 State Bar of
More informationStability Testing for Pre-Clinical and Early Phase Clinical Drug Products
Microrite, Inc. brings you this unique learning experience in Stability Testing for Pre-Clinical and Early Phase Clinical Drug Products; Part of Microrite s step-by-step webinar series. Stability Testing
More informationNonclinical and Clinical Strategies in First-in-Human Dosing of Large and Small Molecules
Nonclinical and Clinical Strategies in First-in-Human Dosing of Large and Small Molecules April 19-21, 2010 Tutorials: April 18, 2010 April 4-6, 2011 Marriott Bethesda North Hotel & Conference Center,
More informationMedia Opportunities from
Media Opportunities from Dear industry supporter: Thank you for your interest in the Direct Gardening Association s Sponsorship and advertising program. We are excited to present you with the DGA Marketing
More informationKOL Relationship. Cross-Functional Collaborative Strategies to Identify, Engage and Grow Thought Leader Networks in a Highly Regulated Environment
June 24-25, 2014 Philadelphia PA, Hyatt at the Bellevue Fifth KOL Relationship Cross-Functional Collaborative Strategies to Identify, Engage and Grow Thought Leader Networks in a Highly Regulated Environment
More informationPartnering ACOs. with Summit. 4th. October 27-28, 2014 Hotel Palomar Los Angeles-Westwood, Los Angeles, CA
4th Partnering ACOs October 27-28, 2014 Hotel Palomar Los Angeles-Westwood, Los Angeles, CA with Summit Improve Patient Outcomes and Reduce Costs While Building Valuable Strategic Cross Industry Collaborations
More informationStrategic Partnerships
2nd Strategic Partnerships for Drug Repurposing Forum Discover the Latest Indications for Repurposing, Rescuing and Repositioning Existing Drugs to Explore New Innovations October 26-27, 2017 / Hyatt Regency
More information38th Annual Columbus Chapter ASIS Seminar and Exhibits
May 18, 2017 38th Annual Columbus Chapter ASIS Seminar and Exhibits EDUCATION TECHNOLOGY EXHIBITS NETWORKING Hosted by the Columbus Chapter ASIS this one day event is the areas largest seminar with quality
More informationFinding the right partner for preclinical into phase I. Facts, Threats & Opportunities
Nuvisan Presentation Outsourcing and Clinical Trials DACH, 9th October 2018 Finding the right partner for preclinical into phase I Facts, Threats & Opportunities 9 October 2018 1 PASSIONATE PEOPLE FOR
More informationApproach, Information needed and criteria- suggested by the members of the IQ dissolution WG
Framework for setting Clinically relevant Dissolution Specification (CRS) Approach, Information needed and criteria- suggested by the members of the IQ dissolution WG Andreas Abend Merck Research Labs
More informationPPC Best Practices Conference
New! RISK ASSESSMENT REVISITED PPC Best Practices Conference Train with the experts! Cutting-edge content New Orleans, LA Sept 25 26 Las Vegas, NV Nov 6 7 from the Tax & Accounting business of Thomson
More informationWHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability
2017 WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability Eric C Buxton Clinical Associate Professor University of Wisconsin Madison School of Pharmacy, Division of Pharmacy
More informationC L A R I D E N October 2012 Knowledge for the world business leaders
C L A R I D E N 18-19 October 2012 Knowledge for the world business leaders Shangri-La Hotel, Singapore Creating Winning Strategies for Pharmaceutical Launch Success: An Integrated Approach from Strategic
More informationDRUG SOLUBILITY EXECUTIVE SUMMARY
DRUG SOLUBILITY Utilising a high throughput screening platform to determine the optimum pharmaceutical excipients in the development of liquid formulations EXECUTIVE SUMMARY Drugs are small molecules or
More information37th Annual Columbus Chapter ASIS Seminar and Exhibits
May 12, 2016 37th Annual Columbus Chapter ASIS Seminar and Exhibits EDUCATION TECHNOLOGY EXHIBITS NETWORKING Hosted by the Columbus Chapter ASIS this one day event is the areas largest seminar with quality
More informationPHARMACEUTICAL CHEMISTRY & DRUG DISCOVERY
SPONSORSHIP & EXHIBITION 2019 Pharma Chem Congress 2019 Theme: Transformative Experience on Pharmaceutical Chemistry and Drug Delivery 2 nd International Conference on PHARMACEUTICAL CHEMISTRY & DRUG DISCOVERY
More informationSetting Specifications and. Acceptance Criteria November 2015, Berlin, Germany ECA. Highlights:
ECA ACADEMY Speakers: Dr Thomas Fürst Boehringer Ingelheim Pharma, Dr Hiltrud Horn Horn Pharmaceutical Consulting, Dr Bettina Pahlen Quality x Pharma Consulting GmbH, Dr Wilhelm Schlumbohm Berlin, Dr Thomas
More informationPHARMACEUTICAL CHEMISTRY & DRUG DISCOVERY
SPONSORSHIP & EXHIBITION 2019 Pharma Chem Congress 2019 Theme: Transformative Experience on Pharmaceutical Chemistry and Drug Delivery 2 nd International Conference on PHARMACEUTICAL CHEMISTRY & DRUG DISCOVERY
More informationConference Sponsorship & Exhibit Opportunities
Conference Sponsorship & Exhibit Opportunities October 22-25, 2018 Tampa Marriott Waterside Tampa, FL SPONSORSHIP OPPORTUNITIES Thank you for your interest in sponsorship. We hope you ll join us at the
More informationEffective Stakeholders Management for Project, Program & PMO Managers
This unique 2-day practical workshop is designed to help project managers to successfully deliver project results by learning how to influence others, effectively communicate and sell their ideas to gain
More informationOutline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD
CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables
More informationSPONSORSHIP. Educational Conference. & Expo. 34th Annual National. OCTOBER 5-7, 2014 J.W. Marriott Desert Ridge Resort & Spa Phoenix, AZ
34th Annual National Educational Conference & Expo OCTOBER 5-7, 2014 J.W. Marriott Desert Ridge Resort & Spa Phoenix, AZ SPONSORSHIP www.siia.org OPPORTUNITIES 800.851.7789 SPONSORSHIPS 1700 ATTENDEES
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationSUMMIT October 5-6, 2015 Hilton Boston Back Bay Boston, MA
From the Creators of The Drug Formulation & Bioavailability Series 2nd Annual BIOEQUIVALENCE Innovative Approaches Toward Developing Bioequivalent Drugs While Comprehensively Maintaining Regulatory Compliance
More informationPLATNIUM GOLD 2017 SPONSOR OPPORTUNITIES. Keynote Speaker: $35,000 and up** Casino Night: $35,000. Advisory Board Dinner: $20,000
PLATNIUM Keynote Speaker: $35,000 and up** 2017 SPONSOR OPPORTUNITIES Casino Night: $35,000 30 pre-autographed items by Keynote Speaker (items to be provided by sponsor) Pre-Con meeting with Keynote Speaker
More information